



NDA 19-928/SLR-002

Bracco Diagnostics Inc.
Attention: Melanie Benson
Director, US Regulatory Affairs
P.O. Box 5225
Princeton, NJ 08543-5225

Dear Ms. Benson:

Please refer to your supplemental new drug application dated April 26, 2002, received April 29, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for CardioTec (Kit for the Preparation of technetium Tc99m Teboroxime).

We acknowledge receipt of your submissions dated May 3, June 27, October 21, 2002, February 3, April 2, 11, and 14, 2003.

Your submission of October 21, 2002, constituted a complete response to our July 10, 2002, action letter.

This supplemental new drug application provides for strengthening of the Adverse Reactions section of the package insert to concur with the current Investigator's Brochure.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with revisions listed below.

The **ADVERSE REACTIONS** section of the package insert will be amended to state the following:

“Of the 1537 patients that were evaluated during the clinical development of CardioTec, 7 patients experienced serious adverse events of whom 4 patients had myocardial infarction, one each had hyperglycemia and arthralgia, and one patient experienced dizziness, nausea and lightheadedness. It was not possible to determine the underlying cause for these serious adverse events.

In completed clinical trials, adverse events were evaluated in 1413 adults. The most commonly reported non-serious adverse events were chest pain and nausea, both with the frequency of 0.4%. The following were adverse events by body systems:

Body as a Whole (1.0%): back pain, chest pain, chest tightness, fatigue, injection site burning, injection site pain, shakiness; **Cardiovascular (1.0%):** angina, AV block, blood pressure decreased, blood pressure increased, flushing, heart rate decreased, hypertension, myocardial infarction, palpitation, postural hypotension; **Gastrointestinal (0.6%):** diarrhea, nausea, vomiting; **Musculoskeletal (0.3%):** arthralgia, jaw pain; **Nervous (0.6%):** balance disturbance, dizziness,

*hypoesthesia, paresthesia, syncope, taste disturbance; **Respiratory (0.3%):** dyspnea, wheezing; **Skin and Appendages (0.2%):** clamminess, dermatitis, face edema; **Vision (0.1%):** eye pain.”*

The final printed labeling (FPL) must be identical, and include the revisions listed, to the submitted labeling (package insert submitted April 14, 2003). These revisions are terms of the approval of this application.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 19-928/SLR-002." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Patricia A. Stewart, Regulatory Project Manager, at (301) 827-7510.

Sincerely,

{See appended electronic signature page}

Sally Loewke, M.D.
Deputy Director
Division of Medical Imaging and
Radiopharmaceutical Drug Products
Office of Drug Evaluation ODE III
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Sally Loewke
4/17/03 08:29:30 AM